CXS Chemgenex Fpo

ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) today announced that Mr. Jean-Luc T�tard, the President of the Stragen Group of companies, has joined the company�s Board of Directors effective immediately. Mr. T�tard is an experienced senior executive and director with more than 35 years' experience in the pharmaceutical and biotechnology industries. As founding Chief Executive Officer of Stragen Chemical SA and Stragen Pharma SA, Mr. T�tard has, over a period of 18 years, guided the growth and success of the Stragen Group as it has expanded to become a European leader in developing and distributing generic pharmaceuticals. The Stragen Group has obtained approximately 200 drug marketing approvals globally and has operations in Switzerland, France, the UK, Germany, Scandinavia, Russia and Canada. Prior to founding the Stragen Group Mr. T�tard worked for the French pharmaceutical company Sanofi (now Sanofi-Aventis) as a senior executive in pharmaceutical manufacturing. �As ChemGenex looks to complete the clinical trials of omacetaxine mepesuccinate over the coming months and moves towards FDA and EMEA submission, Jean-Luc�s experience in marketing, distribution and corporate development, particularly in the European context, will be an invaluable asset for us,� said Greg Collier, Ph.D., Chief Executive Officer and Managing Director. �We welcome Jean-Luc to the Board of Directors and look forward to his contributions across the organization.� �This is an exciting time to be joining ChemGenex,� Mr. T�tard said. �I look forward to working with management and my fellow Directors to realize the value of omacetaxine and the company�s other assets, and to continue to build upon the successes reported over the past year.� About ChemGenex Pharmaceuticals Limited (http://www.chemgenex.com) ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing personalized oncology medicines. ChemGenex harnesses the power of genomics both to discover novel targets and drug compounds, and in clinical trials to develop more individualized treatment outcomes. ChemGenex�s lead compound, omacetaxine mepesuccinate (formerly known as Ceflatonin�), is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML). ChemGenex has a second anticancer compound, amonafide dihydrochloride (formerly known as Quinamed�) which is in phase 2 clinical development for various solid cancers, and a portfolio of assets in pre-clinical development. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP". Details on the clinical trials can be accessed from the following websites: http://clinicaltrials.gov/ct2/show/NCT00375219?term= homoharringtonine&rank=9 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) and http://www.tkiresistantcmltrials.com Safe Harbor Statement Certain statements made herein that use the words �estimate�, �project�, �intend�, �expect�, �believe� and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company�s technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company�s technology, the market for the company�s products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management�s current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.